相关实验视频
Updated: Jun 10, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
248
多发性骨髓瘤和新的检查点抑制剂在免疫治疗中的潜力
Ali N Kamali1,2, Haleh Hamedifar1,2, Michael Eisenhut3
1CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Therapeutic advances in vaccines and immunotherapy
|October 14, 2024
概括
多发性髓瘤免疫疗法由于T细胞耗尽而表现出有限的成功. 这篇评论探讨了像TIGIT,Tim-3和LAG-3这样的免疫检查点,以改善这种骨髓癌的治疗方法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤 (MM) 是成年人中第二常见的血液性恶性瘤.
- 目前用于MM的免疫疗法已显示出有限的疗效和显著的副作用,特别是在晚期.
- 瘤微环境 (TME) 中的T细胞耗尽标记是MM进展的关键因素.
研究的目的:
- 审查MM中五个关键抑制性免疫检查点分子的机制.
- 讨论这些检查点在MM病原和癌症途径中的新兴作用.
- 要总结最近的临床试验,涉及MM的免疫检查点抑制剂.
主要方法:
- 关于免疫检查点抑制剂及其在癌症中的作用的文献综述,特别是MM.
- 对五种抑制分子的分析:TIGIT,Tim-3,LAG-3,VISTA和KIR.
- 在MM免疫治疗的背景下对双特异性T细胞抗体 (BsAbs) 的检查.
主要成果:
- 免疫检查点抑制剂在MM治疗中面临挑战,原因是副作用过多或疗效低.
- 淋巴细胞耗尽标记显著影响MM瘤微环境.
- 理解这些检查点对于开发有效的MM免疫疗法至关重要.
结论:
- 针对TIGIT,Tim-3和LAG-3等免疫检查点,为改善MM免疫疗法提供了一个有希望的途径.
- 需要进一步研究这些检查点的生物学和临床应用.
- 双特异性T细胞抗体提供了一种潜在的策略,以克服MM的免疫逃避.
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K

